SEC Form 4 · accession 0001213900-17-011531
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saiid Zarrabian
Officer — Interim CEO · Director
Period of report
Nov 3, 2017
Accepted (ET)
Nov 7, 2017 · 8:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $0.87 | Nov 3, 2017 | A | 120,000 | A | — | Nov 3, 2027 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1The option vests in full on the first anniversary of the date of grant.